Overview

Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis

Status:
Completed

Trial end date:
2018-09-19

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the efficacy and safety of roxadustat compared with active control (epoetin alfa) for the maintenance treatment of anemia in participants with ESRD on dialysis.

Phase:

Phase 3

Details

Lead Sponsor:

FibroGen

Collaborators:

Astellas Pharma Europe B.V.
AstraZeneca

Treatments:

Epoetin Alfa